United States

People: Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

16 Mar 2018
Change (% chg)

$0.01 (+0.66%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chevallard, Daniel 

Mr. Daniel Chevallard serves as Chief Financial Officer, Principal Financial and Accounting Officer of the Company. Mr. Chevallard had served as our Vice President, Finance and Accounting since May 2013 and as Vice President, Accounting and Financial Reporting commencing in December 2012. Prior to joining Regulus, Mr. Chevallard held various senior roles in corporate finance, accounting and financial reporting including Controller and Senior Director, Finance with Prometheus Laboratories Inc. (acquired by Nestle´ Health Science in July 2011) from April 2006 to December 2012. From September 2001 to April 2006, Mr. Chevallard was employed by public accounting firm Ernst & Young, LLP in their assurance services practice. Mr. Chevallard received his Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant in the state of California.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --